Junxing Chay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Junxing Chay has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Ngiap Chuan Tan
SingHealth Polyclinics, Singapore 150167, Singapore
4 shared publications - Chek Hooi Wong
Geriatric Education and Research Institute, Singapore
3 shared publications - Ecosse Luc Lamoureux
Singapore Eye Research Institute, Singapore, Singapore
3 shared publications - Eric Andrew Finkelstein
Lien Centre for Palliative Care Duke‐NUS Medical School Singapore
3 shared publications - Eva Katie Fenwick
Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore
3 shared publications - Grace Sum
Geriatric Education & Research Institute, Singapore, Singapore
3 shared publications
Latest Publications
- Open Access
- 22 October 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (7) , 697
Understanding the Prevalence, Factors, and Patient-Centered and Economic Outcomes of Prefrailty and Frailty in Community-Dwelling Older Singaporean Adults
Introduction: The objective of this study was to determine the prevalence, factors associated with, and patient-centered and economic outcomes of prefrailty and frailty in a multi-ethnic population of community-dwelling older Singaporean adults aged ≥60 years. Methods: We included 2110 participants (mean age ± SD: 72.4 ± 8.1 years; 52.6% female) from the cross-sectional Population Health and Eye Disease Profile in Elderly Singaporeans (PIONEER) study (2017 to 2022). A modified Fried frailty cross-sectional phenotype classification was used to categorize participants as prefrail or frail, based on them having 1–2 or ≥3 of the following characteristics: underweight (body mass index < 18.5 kg/m2), slowness (sex-specific lowest quintile of time taken to complete a 4 m gait speed test), weakness (sex-specific lowest quintile of grip strength), self-reported exhaustion (score < 10 in the Vitality domain of the 12-item short-form survey), and low physical activity duration (sex-specific lowest quintile of those individuals a non-zero duration). Sociodemographic, clinical and lifestyle factors, patient-centered (health-related quality of life, functional disability, life-space mobility, depressive symptoms, falls and perceived economic hardship) and economic (healthcare expenditure, work productivity loss) outcomes were assessed via standardized clinical testing and/or validated questionnaires. Ordinal logistic regression models with dominance analysis, linear, negative binomial and two-part regression models were utilized to explore the associated factors and patient-centered and economic outcomes of prefrailty and frailty, respectively. Results: The census-adjusted prevalence of prefrailty and frailty were 64.6% and 11.0%, respectively. Age, minority ethnicity, and cognitive impairment contributed ≥70% of the total model effect, with the remaining contributors being female sex, diabetes, and polypharmacy. The frailty severity spectrum (none, prefrailty and frailty) were also associated with 1.74% to 164.49% significantly poorer outcomes across the majority of patient-centered outcomes assessed. No significant overall differences in annual healthcare expenditure and productivity loss were observed. Conclusions: Over half and one in ten of community-dwelling older Singaporeans were prefrail and frail, respectively, with both groups experiencing substantially poorer patient-centered outcomes. Older age, female sex and cognitive impairment were associated with greater odds of presenting along the frailty severity spectrum and warrants further verification through longitudinal investigations.
- 22 October 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (7) , 697
Open AccessUnderstanding the Prevalence, Factors, and Patient-Centered and Economic Outcomes of Prefrailty and Frailty in Community-Dwelling Older Singaporean Adults
Introduction: The objective of this study was to determine the prevalence, factors associated with, and patient-centered and economic outcomes of prefrailty and frailty in a multi-ethnic population of community-dwelling older Singaporean adults aged ≥60 years. Methods: We included 2110 participants (mean age ± SD: 72.4 ± 8.1 years; 52.6% female) from the cross-sectional Population Health and Eye Disease Profile in Elderly Singaporeans (PIONEER) study (2017 to 2022). A modified Fried frailty cross-sectional phenotype classification was used to categorize participants as prefrail or frail, based on them having 1–2 or ≥3 of the following characteristics: underweight (body mass index < 18.5 kg/m2), slowness (sex-specific lowest quintile of time taken to complete a 4 m gait speed test), weakness (sex-specific lowest quintile of grip strength), self-reported exhaustion (score < 10 in the Vitality domain of the 12-item short-form survey), and low physical activity duration (sex-specific lowest quintile of those individuals a non-zero duration). Sociodemographic, clinical and lifestyle factors, patient-centered (health-related quality of life, functional disability, life-space mobility, depressive symptoms, falls and perceived economic hardship) and economic (healthcare expenditure, work productivity loss) outcomes were assessed via standardized clinical testing and/or validated questionnaires. Ordinal logistic regression models with dominance analysis, linear, negative binomial and two-part regression models were utilized to explore the associated factors and patient-centered and economic outcomes of prefrailty and frailty, respectively. Results: The census-adjusted prevalence of prefrailty and frailty were 64.6% and 11.0%, respectively. Age, minority ethnicity, and cognitive impairment contributed ≥70% of the total model effect, with the remaining contributors being female sex, diabetes, and polypharmacy. The frailty severity spectrum (none, prefrailty and frailty) were also associated with 1.74% to 164.49% significantly poorer outcomes across the majority of patient-centered outcomes assessed. No significant overall differences in annual healthcare expenditure and productivity loss were observed. Conclusions: Over half and one in ten of community-dwelling older Singaporeans were prefrail and frail, respectively, with both groups experiencing substantially poorer patient-centered outcomes. Older age, female sex and cognitive impairment were associated with greater odds of presenting along the frailty severity spectrum and warrants further verification through longitudinal investigations.
- Open Access
- 28 August 2026
- Published by Elsevier in Surgery for Obesity and Related Diseases
Cost-effectiveness of endoscopic sleeve gastroplasty using a disease progression model
- 28 August 2026
- Published by Elsevier in Surgery for Obesity and Related Diseases
Open AccessCost-effectiveness of endoscopic sleeve gastroplasty using a disease progression model
- Open Access
- 8 May 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14, e63253
Nonadherence to Diabetes Complications Screening in a Multiethnic Asian Population: Protocol for a Mixed Methods Prospective Study
Background: Yearly screening for microvascular complications of diabetes mellitus (DM), namely diabetic retinopathy (DR), diabetic nephropathy (DN), and diabetic foot complications (DFC), is recommended to reduce their incidence, and delay or prevent their progression. Poor adherence to screening is common, but prospective data on the magnitude and predictors of nonadherence to DR, DN, and DFC screening in Singapore are unavailable. Objective: The Understanding Non-Adherence to Diabetes Complications Screening study aims to determine the rates, predictors, and clinical and economic impact of nonadherence to diabetic complications screening in patients with type 2 diabetes in Singapore. The study describes the methodology and participants’ baseline characteristics that may be associated with nonadherence to DM complications screening. Methods: In this prospective, mixed methods, clinic-based study, patients who underwent DR, DN, or DFC screening and were offered an annual rescreening appointment, were recruited from 6 primary care centers. Patients’ sociodemographic, medical, clinical, and patient-reported characteristics were recorded at baseline. Nonadherence to DR, DN, or DFC screening is defined as not attending the annual rescreening appointment within 4 months of the scheduled rescreening date. Adherence and clinical data will be recorded at 16 months post enrollment. Additionally, selected participants and health care professionals will undergo qualitative interviews to elicit barriers or facilitators of adherence to rescreening. Results: Ethical approval was obtained in November 2016. Study enrollment commenced across the 6 sites between June 2018 and February 2019, and baseline data collection ended at all sites in January 2020. 974 eligible patients (2123 screenings; median age of 61.0, IQR 55.0-67.0 years; male: 515, 52.9%; Chinese: 624, 64.1%) consented and completed the baseline assessment. Of these, 734 (75.4%), 603 (61.9%), and 786 (80.7%) attended DR, DN, and DFC screening, respectively. Most (n=793, 81.4%) attended more than 1 complication screening on the same day; had received secondary or lower education (n=701, 71.9%); had hypertension (n=711, 73.4%) and dyslipidemia (n=828, 85.1%); and 43.1% (n=419) were obese (BMI>27.5 kg/m2). Median DM duration and hemoglobin A1c levels were 6.3 (IQR 3.0-12.0) years and 6.9% (6.4%-7.6%), respectively. Over half (n=532, 55.1%) had not received prior DM education. Furthermore, participants reported low levels of diabetes-related self-efficacy (median 1.4, IQR 1.0-3.9 out of 5). Conclusions: At baseline, we have successfully enrolled almost 1000 patients with type 2 diabetes scheduled for annual DR, DN, or DFC rescreening, and potential predictors of nonadherence to rescreening were systematically collected. Follow-up phases will focus on establishing the rates and associated modifiable predictors of nonadherence to DR, DN, or DFC rescreening, which may inform program initiatives. International Registered Report Identifier (IRRID): DERR1-10.2196/63253
- 8 May 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14, e63253
Open AccessNonadherence to Diabetes Complications Screening in a Multiethnic Asian Population: Protocol for a Mixed Methods Prospective Study
Background: Yearly screening for microvascular complications of diabetes mellitus (DM), namely diabetic retinopathy (DR), diabetic nephropathy (DN), and diabetic foot complications (DFC), is recommended to reduce their incidence, and delay or prevent their progression. Poor adherence to screening is common, but prospective data on the magnitude and predictors of nonadherence to DR, DN, and DFC screening in Singapore are unavailable. Objective: The Understanding Non-Adherence to Diabetes Complications Screening study aims to determine the rates, predictors, and clinical and economic impact of nonadherence to diabetic complications screening in patients with type 2 diabetes in Singapore. The study describes the methodology and participants’ baseline characteristics that may be associated with nonadherence to DM complications screening. Methods: In this prospective, mixed methods, clinic-based study, patients who underwent DR, DN, or DFC screening and were offered an annual rescreening appointment, were recruited from 6 primary care centers. Patients’ sociodemographic, medical, clinical, and patient-reported characteristics were recorded at baseline. Nonadherence to DR, DN, or DFC screening is defined as not attending the annual rescreening appointment within 4 months of the scheduled rescreening date. Adherence and clinical data will be recorded at 16 months post enrollment. Additionally, selected participants and health care professionals will undergo qualitative interviews to elicit barriers or facilitators of adherence to rescreening. Results: Ethical approval was obtained in November 2016. Study enrollment commenced across the 6 sites between June 2018 and February 2019, and baseline data collection ended at all sites in January 2020. 974 eligible patients (2123 screenings; median age of 61.0, IQR 55.0-67.0 years; male: 515, 52.9%; Chinese: 624, 64.1%) consented and completed the baseline assessment. Of these, 734 (75.4%), 603 (61.9%), and 786 (80.7%) attended DR, DN, and DFC screening, respectively. Most (n=793, 81.4%) attended more than 1 complication screening on the same day; had received secondary or lower education (n=701, 71.9%); had hypertension (n=711, 73.4%) and dyslipidemia (n=828, 85.1%); and 43.1% (n=419) were obese (BMI>27.5 kg/m2). Median DM duration and hemoglobin A1c levels were 6.3 (IQR 3.0-12.0) years and 6.9% (6.4%-7.6%), respectively. Over half (n=532, 55.1%) had not received prior DM education. Furthermore, participants reported low levels of diabetes-related self-efficacy (median 1.4, IQR 1.0-3.9 out of 5). Conclusions: At baseline, we have successfully enrolled almost 1000 patients with type 2 diabetes scheduled for annual DR, DN, or DFC rescreening, and potential predictors of nonadherence to rescreening were systematically collected. Follow-up phases will focus on establishing the rates and associated modifiable predictors of nonadherence to DR, DN, or DFC rescreening, which may inform program initiatives. International Registered Report Identifier (IRRID): DERR1-10.2196/63253
- Open Access
- 17 July 2024
- Published by Elsevier in The Lancet Global Health
- Vol. 12 (8) , e1331-e1342
Cost-effectiveness of group medical visits and microfinance interventions versus usual care to manage hypertension in Kenya: a secondary modelling analysis of data from the Bridging Income Generation with Group Integrated Care (BIGPIC) trial
- 17 July 2024
- Published by Elsevier in The Lancet Global Health
- Vol. 12 (8) , e1331-e1342
Open AccessCost-effectiveness of group medical visits and microfinance interventions versus usual care to manage hypertension in Kenya: a secondary modelling analysis of data from the Bridging Income Generation with Group Integrated Care (BIGPIC) trial
- Open Access
- 13 June 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Nonadherence to Diabetes Complications Screening in a Multiethnic Asian Population: Protocol for a Mixed Methods Prospective Study (Preprint)
BACKGROUND Yearly screening for microvascular complications of diabetes mellitus (DM), namely diabetic retinopathy (DR), diabetic nephropathy (DN), and diabetic foot complications (DFC), is recommended to reduce their incidence, and delay or prevent their progression. Poor adherence to screening is common, but prospective data on the magnitude and predictors of nonadherence to DR, DN, and DFC screening in Singapore are unavailable. OBJECTIVE The Understanding Non-Adherence to Diabetes Complications Screening study aims to determine the rates, predictors, and clinical and economic impact of nonadherence to diabetic complications screening in patients with type 2 diabetes in Singapore. The study describes the methodology and participants’ baseline characteristics that may be associated with nonadherence to DM complications screening. METHODS In this prospective, mixed methods, clinic-based study, patients who underwent DR, DN, or DFC screening and were offered an annual rescreening appointment, were recruited from 6 primary care centers. Patients’ sociodemographic, medical, clinical, and patient-reported characteristics were recorded at baseline. Nonadherence to DR, DN, or DFC screening is defined as not attending the annual rescreening appointment within 4 months of the scheduled rescreening date. Adherence and clinical data will be recorded at 16 months post enrollment. Additionally, selected participants and health care professionals will undergo qualitative interviews to elicit barriers or facilitators of adherence to rescreening. RESULTS Ethical approval was obtained in November 2016. Study enrollment commenced across the 6 sites between June 2018 and February 2019, and baseline data collection ended at all sites in January 2020. 974 eligible patients (2123 screenings; median age of 61.0, IQR 55.0-67.0 years; male: 515, 52.9%; Chinese: 624, 64.1%) consented and completed the baseline assessment. Of these, 734 (75.4%), 603 (61.9%), and 786 (80.7%) attended DR, DN, and DFC screening, respectively. Most (n=793, 81.4%) attended more than 1 complication screening on the same day; had received secondary or lower education (n=701, 71.9%); had hypertension (n=711, 73.4%) and dyslipidemia (n=828, 85.1%); and 43.1% (n=419) were obese (BMI>27.5 kg/m2). Median DM duration and hemoglobin A1c levels were 6.3 (IQR 3.0-12.0) years and 6.9% (6.4%-7.6%), respectively. Over half (n=532, 55.1%) had not received prior DM education. Furthermore, participants reported low levels of diabetes-related self-efficacy (median 1.4, IQR 1.0-3.9 out of 5). CONCLUSIONS At baseline, we have successfully enrolled almost 1000 patients with type 2 diabetes scheduled for annual DR, DN, or DFC rescreening, and potential predictors of nonadherence to rescreening were systematically collected. Follow-up phases will focus on establishing the rates and associated modifiable predictors of nonadherence to DR, DN, or DFC rescreening, which may inform program initiatives. INTERNATIONAL REGISTERED REPORT DERR1-10.2196/63253
- 13 June 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessNonadherence to Diabetes Complications Screening in a Multiethnic Asian Population: Protocol for a Mixed Methods Prospective Study (Preprint)
BACKGROUND Yearly screening for microvascular complications of diabetes mellitus (DM), namely diabetic retinopathy (DR), diabetic nephropathy (DN), and diabetic foot complications (DFC), is recommended to reduce their incidence, and delay or prevent their progression. Poor adherence to screening is common, but prospective data on the magnitude and predictors of nonadherence to DR, DN, and DFC screening in Singapore are unavailable. OBJECTIVE The Understanding Non-Adherence to Diabetes Complications Screening study aims to determine the rates, predictors, and clinical and economic impact of nonadherence to diabetic complications screening in patients with type 2 diabetes in Singapore. The study describes the methodology and participants’ baseline characteristics that may be associated with nonadherence to DM complications screening. METHODS In this prospective, mixed methods, clinic-based study, patients who underwent DR, DN, or DFC screening and were offered an annual rescreening appointment, were recruited from 6 primary care centers. Patients’ sociodemographic, medical, clinical, and patient-reported characteristics were recorded at baseline. Nonadherence to DR, DN, or DFC screening is defined as not attending the annual rescreening appointment within 4 months of the scheduled rescreening date. Adherence and clinical data will be recorded at 16 months post enrollment. Additionally, selected participants and health care professionals will undergo qualitative interviews to elicit barriers or facilitators of adherence to rescreening. RESULTS Ethical approval was obtained in November 2016. Study enrollment commenced across the 6 sites between June 2018 and February 2019, and baseline data collection ended at all sites in January 2020. 974 eligible patients (2123 screenings; median age of 61.0, IQR 55.0-67.0 years; male: 515, 52.9%; Chinese: 624, 64.1%) consented and completed the baseline assessment. Of these, 734 (75.4%), 603 (61.9%), and 786 (80.7%) attended DR, DN, and DFC screening, respectively. Most (n=793, 81.4%) attended more than 1 complication screening on the same day; had received secondary or lower education (n=701, 71.9%); had hypertension (n=711, 73.4%) and dyslipidemia (n=828, 85.1%); and 43.1% (n=419) were obese (BMI>27.5 kg/m2). Median DM duration and hemoglobin A1c levels were 6.3 (IQR 3.0-12.0) years and 6.9% (6.4%-7.6%), respectively. Over half (n=532, 55.1%) had not received prior DM education. Furthermore, participants reported low levels of diabetes-related self-efficacy (median 1.4, IQR 1.0-3.9 out of 5). CONCLUSIONS At baseline, we have successfully enrolled almost 1000 patients with type 2 diabetes scheduled for annual DR, DN, or DFC rescreening, and potential predictors of nonadherence to rescreening were systematically collected. Follow-up phases will focus on establishing the rates and associated modifiable predictors of nonadherence to DR, DN, or DFC rescreening, which may inform program initiatives. INTERNATIONAL REGISTERED REPORT DERR1-10.2196/63253
- Open Access
- 16 April 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (8) , e033631
Cost‐Effectiveness of a Multicomponent Primary Care Intervention for Hypertension
Background: The SingHypertension primary care clinic intervention, which consisted of clinician training in hypertension management, subsidized single‐pill combination medications, nurse‐delivered motivational conversations and telephone follow‐ups, improved blood pressure control and cardiovascular disease (CVD) risk scores relative to usual care among patients with uncontrolled hypertension in Singapore. This study quantified the incremental cost‐effectiveness, in terms of incremental cost per unit reduction disability‐adjusted life years, of SingHypertension relative to usual care for patients with hypertension from the health system perspective. Methods and Results: We developed a Markov model to simulate CVD events and associated outcomes for a hypothetical cohort of patients over a 10‐year period. Costs were measured in US dollars, and effectiveness was measured in disability‐adjusted life years averted. We present base‐case results and conducted deterministic and probabilistic sensitivity analyses. Based on a willingness‐to‐pay threshold of US $55 500 per DALY averted, SingHypertension was cost‐effective for patients with hypertension (incremental cost‐effectiveness ratio: US $24 765 per disability‐adjusted life year averted) relative to usual care. This result held even if risk reduction was assumed to decline linearly to 0 over 10 years but not sooner than 7 years. Incremental cost‐effectiveness ratios were most sensitive to the magnitude of the reduction in CVD risk; at least a 0.13% to 0.16% point reduction in 10‐year CVD risk is required for cost‐effectiveness. Probabilistic sensitivity analysis indicates that SingHypertension has a 78% chance of being cost‐effective at the willingness‐to‐pay threshold. Conclusions: SingHypertension represents good value for the money for reducing CVD incidence, morbidity, and mortality and should be considered for wide‐scale implementation in Singapore and possibly other countries. Registration Information: REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02972619.
- 16 April 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (8) , e033631
Open AccessCost‐Effectiveness of a Multicomponent Primary Care Intervention for Hypertension
Background: The SingHypertension primary care clinic intervention, which consisted of clinician training in hypertension management, subsidized single‐pill combination medications, nurse‐delivered motivational conversations and telephone follow‐ups, improved blood pressure control and cardiovascular disease (CVD) risk scores relative to usual care among patients with uncontrolled hypertension in Singapore. This study quantified the incremental cost‐effectiveness, in terms of incremental cost per unit reduction disability‐adjusted life years, of SingHypertension relative to usual care for patients with hypertension from the health system perspective. Methods and Results: We developed a Markov model to simulate CVD events and associated outcomes for a hypothetical cohort of patients over a 10‐year period. Costs were measured in US dollars, and effectiveness was measured in disability‐adjusted life years averted. We present base‐case results and conducted deterministic and probabilistic sensitivity analyses. Based on a willingness‐to‐pay threshold of US $55 500 per DALY averted, SingHypertension was cost‐effective for patients with hypertension (incremental cost‐effectiveness ratio: US $24 765 per disability‐adjusted life year averted) relative to usual care. This result held even if risk reduction was assumed to decline linearly to 0 over 10 years but not sooner than 7 years. Incremental cost‐effectiveness ratios were most sensitive to the magnitude of the reduction in CVD risk; at least a 0.13% to 0.16% point reduction in 10‐year CVD risk is required for cost‐effectiveness. Probabilistic sensitivity analysis indicates that SingHypertension has a 78% chance of being cost‐effective at the willingness‐to‐pay threshold. Conclusions: SingHypertension represents good value for the money for reducing CVD incidence, morbidity, and mortality and should be considered for wide‐scale implementation in Singapore and possibly other countries. Registration Information: REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02972619.
- Open Access
- 5 March 2024
- Published by Wiley in Nephrology
- Vol. 29 (5) , 278-287
Cost‐effectiveness of sodium zirconium cyclosilicate for advanced chronic kidney patients in Singapore
Introduction: Hyperkalaemia (HK) is prevalent among patients with chronic kidney disease (CKD) and chronic heart failure, especially if they are treated with renin‐angiotensin‐aldosterone system inhibitors (RAASi). This study evaluated the cost‐effectiveness of a newly developed anti‐HK therapy, sodium zirconium cyclosilicate (SZC), to the current standard of care for treating HK in advanced CKD patients from the Singapore health system perspective.Methods: We adapted a global microsimulation model to simulate individual patients' potassium level trajectories with baseline potassium ≥5.5 mmol/L, CKD progression, changes in treatment, and other fatal and non‐fatal events. Effectiveness data was derived from ZS‐004 and ZS‐005 trials. Model parameters were localised using CKD patients' administrative and medical records at the Singapore General Hospital Department of Renal Medicine. We estimated the lifetime cost and quality‐adjusted life years (QALYs) of each HK treatment, and the incremental cost‐effectiveness ratio of SZC.Results: SZC demonstrated cost‐effectiveness with an incremental cost‐effectiveness ratsio of SGD 45 068 per QALY over a lifetime horizon, below the willingness‐to‐pay threshold of SGD 90 000 per QALY. Notably, SZC proved most cost‐effective for patients with less severe CKD who were concurrently using RAASi. Sensitivity analyses confirmed the robustness of the findings, accounting for alternative parameter values and statistical uncertainty.Conclusion: This study establishes the cost‐effectiveness of SZC as a treatment for HK, highlighting its potential to mitigate the risk of hyperkalaemia and optimise RAASi therapy. These findings emphasise the value of integrating SZC into the Singapore health system for improved patient outcomes and resource allocation.
- 5 March 2024
- Published by Wiley in Nephrology
- Vol. 29 (5) , 278-287
Open AccessCost‐effectiveness of sodium zirconium cyclosilicate for advanced chronic kidney patients in Singapore
Introduction: Hyperkalaemia (HK) is prevalent among patients with chronic kidney disease (CKD) and chronic heart failure, especially if they are treated with renin‐angiotensin‐aldosterone system inhibitors (RAASi). This study evaluated the cost‐effectiveness of a newly developed anti‐HK therapy, sodium zirconium cyclosilicate (SZC), to the current standard of care for treating HK in advanced CKD patients from the Singapore health system perspective.Methods: We adapted a global microsimulation model to simulate individual patients' potassium level trajectories with baseline potassium ≥5.5 mmol/L, CKD progression, changes in treatment, and other fatal and non‐fatal events. Effectiveness data was derived from ZS‐004 and ZS‐005 trials. Model parameters were localised using CKD patients' administrative and medical records at the Singapore General Hospital Department of Renal Medicine. We estimated the lifetime cost and quality‐adjusted life years (QALYs) of each HK treatment, and the incremental cost‐effectiveness ratio of SZC.Results: SZC demonstrated cost‐effectiveness with an incremental cost‐effectiveness ratsio of SGD 45 068 per QALY over a lifetime horizon, below the willingness‐to‐pay threshold of SGD 90 000 per QALY. Notably, SZC proved most cost‐effective for patients with less severe CKD who were concurrently using RAASi. Sensitivity analyses confirmed the robustness of the findings, accounting for alternative parameter values and statistical uncertainty.Conclusion: This study establishes the cost‐effectiveness of SZC as a treatment for HK, highlighting its potential to mitigate the risk of hyperkalaemia and optimise RAASi therapy. These findings emphasise the value of integrating SZC into the Singapore health system for improved patient outcomes and resource allocation.
- Open Access
- 14 October 2023
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 26 (1) , 1269-1277
Cost-effectiveness of alternative first- and second-line treatments for benign prostatic hyperplasia in Singapore
Background Minimally invasive surgical therapies, such as water vapor thermal therapy (WVTT) and prostatic urethral lift (PUL), are typically second-line options for patients in whom medical management (MM) failed but who are unwilling or unsuitable to undergo invasive transurethral resection of the prostate (TURP). However, the incremental cost-effectiveness of WVTT or PUL as first- or second-line therapy is unknown. We evaluated the incremental cost-effectiveness of alternative first- and second-line treatments for patients with moderate-to-severe benign prostatic hyperplasia (BPH) in Singapore to help policymakers make subsidy decisions based on value for money.Methods We considered six stepped-up treatment strategies, beginning with MM, WVTT, PUL or TURP. In each strategy, patients requiring retreatment advance to a more invasive treatment until TURP, which may be undergone twice. A Markov cohort model was used to simulate transitions between BPH severity states and retreatment, accruing costs and quality-adjusted life-years (QALYs) over a lifetime horizon.Results In moderate patients, strategies beginning with MM had similar cost and effectiveness, and first-line WVTT was incrementally cost-effective to first-line MM (33,307 SGD/QALY). First-line TURP was not incrementally cost-effective to first-line WVTT (159,361 SGD/QALY). For severe patients, WVTT was incrementally cost-effective to MM as a first-line treatment (30,133 SGD/QALY) and to TURP as a second-line treatment following MM (6877 SGD/QALY). TURP was incrementally cost-effective to WVTT as a first-line treatment (48,209 SGD/QALY) in severe patients only. All pathways involving PUL were dominated (higher costs and lower QALYs).Conclusion Based on the common willingness-to-pay threshold of SGD 50,000/QALY, this study demonstrates the cost-effectiveness of WVTT over MM as first-line treatment for patients with moderate or severe BPH, suggesting it represents good value for money and should be considered for subsidy. PUL is not cost-effective as a first- nor second-line treatment. For patients with severe BPH, TURP as first-line is also cost-effective. Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate, common among older men. Its symptoms include difficulties with starting and completing urination, incontinence, frequent and urgent need to urinate. Minimally invasive procedures, such as water vapor thermal therapy (WVTT) and prostatic urethral lift (PUL), are typically offered as second-line options to patients for whom medication has failed but who are unwilling or unsuitable to undergo invasive surgery (transurethral resection of the prostate, TURP). However, whether offering these procedures as first-line options represents good value for money (i.e. cost-effectiveness) is an open question. To address this question and inform subsidy decisions in Singapore, we investigated six stepped-up treatment strategies which differ in first- and second-line treatments. For each strategy, we simulated healthcare costs and quality of life for a cohort of moderate and severe BPH patients over their lifetime, considering the possibility of treatment-related adverse effects and multiple rounds of retreatment. The incremental cost of a unit improvement in quality of life for a strategy relative to the next most expensive one was compared against a willingness-to-pay threshold to determine cost-effectiveness. We found that WVTT was cost-effective relative to medication as a first-line treatment for patients with moderate or severe BPH, suggesting it represents good value for money and should be considered for subsidy. PUL was not cost-effective as first- nor second-line treatment. TURP is cost-effective as first-line for severe BPH patients only.
- 14 October 2023
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 26 (1) , 1269-1277
Open AccessCost-effectiveness of alternative first- and second-line treatments for benign prostatic hyperplasia in Singapore
Background Minimally invasive surgical therapies, such as water vapor thermal therapy (WVTT) and prostatic urethral lift (PUL), are typically second-line options for patients in whom medical management (MM) failed but who are unwilling or unsuitable to undergo invasive transurethral resection of the prostate (TURP). However, the incremental cost-effectiveness of WVTT or PUL as first- or second-line therapy is unknown. We evaluated the incremental cost-effectiveness of alternative first- and second-line treatments for patients with moderate-to-severe benign prostatic hyperplasia (BPH) in Singapore to help policymakers make subsidy decisions based on value for money.Methods We considered six stepped-up treatment strategies, beginning with MM, WVTT, PUL or TURP. In each strategy, patients requiring retreatment advance to a more invasive treatment until TURP, which may be undergone twice. A Markov cohort model was used to simulate transitions between BPH severity states and retreatment, accruing costs and quality-adjusted life-years (QALYs) over a lifetime horizon.Results In moderate patients, strategies beginning with MM had similar cost and effectiveness, and first-line WVTT was incrementally cost-effective to first-line MM (33,307 SGD/QALY). First-line TURP was not incrementally cost-effective to first-line WVTT (159,361 SGD/QALY). For severe patients, WVTT was incrementally cost-effective to MM as a first-line treatment (30,133 SGD/QALY) and to TURP as a second-line treatment following MM (6877 SGD/QALY). TURP was incrementally cost-effective to WVTT as a first-line treatment (48,209 SGD/QALY) in severe patients only. All pathways involving PUL were dominated (higher costs and lower QALYs).Conclusion Based on the common willingness-to-pay threshold of SGD 50,000/QALY, this study demonstrates the cost-effectiveness of WVTT over MM as first-line treatment for patients with moderate or severe BPH, suggesting it represents good value for money and should be considered for subsidy. PUL is not cost-effective as a first- nor second-line treatment. For patients with severe BPH, TURP as first-line is also cost-effective. Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate, common among older men. Its symptoms include difficulties with starting and completing urination, incontinence, frequent and urgent need to urinate. Minimally invasive procedures, such as water vapor thermal therapy (WVTT) and prostatic urethral lift (PUL), are typically offered as second-line options to patients for whom medication has failed but who are unwilling or unsuitable to undergo invasive surgery (transurethral resection of the prostate, TURP). However, whether offering these procedures as first-line options represents good value for money (i.e. cost-effectiveness) is an open question. To address this question and inform subsidy decisions in Singapore, we investigated six stepped-up treatment strategies which differ in first- and second-line treatments. For each strategy, we simulated healthcare costs and quality of life for a cohort of moderate and severe BPH patients over their lifetime, considering the possibility of treatment-related adverse effects and multiple rounds of retreatment. The incremental cost of a unit improvement in quality of life for a strategy relative to the next most expensive one was compared against a willingness-to-pay threshold to determine cost-effectiveness. We found that WVTT was cost-effective relative to medication as a first-line treatment for patients with moderate or severe BPH, suggesting it represents good value for money and should be considered for subsidy. PUL was not cost-effective as first- nor second-line treatment. TURP is cost-effective as first-line for severe BPH patients only.
- Open Access
- 27 September 2023
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 20 (19) , 6848
An Integrated Patient-Centred Medical Home (PCMH) Care Model Reduces Prospective Healthcare Utilisation for Community-Dwelling Older Adults with Complex Needs: A Matched Observational Study in Singapore
The global ageing population is associated with increased health service use. The PCMH care model integrates primary care and home-based care management to deliver comprehensive and personalised healthcare to community-dwelling older adults with bio-psycho-social needs. We examined if an integrated PCMH reduced healthcare utilisation burden of older persons in Singapore. We compared the healthcare utilisation between the intervention group and coarsened exact matched controls for a follow-up of 15 months. Baseline matching covariates included socio-demographics, health status, and past healthcare use. We accounted for COVID-19 social distancing effects on health-seeking behaviour. The intervention group consisted of 165 older adults with complex needs. We analysed national administrative healthcare utilisation data from 2017 to 2020. We applied multivariable zero-inflated regression modelling and presented findings stratified by high (CCI ≥ 5) and low disease burden (CCI < 5). Compared to controls, there were significant reductions in emergency department (β = −0.85; 95%CI = −1.55 to −0.14) and primary care visits (β = −1.70; 95%CI = −2.17 to −1.22) and a decrease in specialist outpatient visits (β = −0.29; 95%CI = −0.64 to 0.07) in the 3-month period immediately after one-year enrolment. The number of acute hospitalisations remained stable. Compared to controls, the intervention group with high and low comorbidity burden had significant decreases in primary care use, while only those with lower comorbidity burden had significant reductions in utilisation of other service types. An integrated PCMH appears beneficial in reducing healthcare utilisation for older persons with complex needs after 1 year in the programme. Future research can explore longer-term utilisation and scalability of the care model.
- 27 September 2023
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 20 (19) , 6848
Open AccessAn Integrated Patient-Centred Medical Home (PCMH) Care Model Reduces Prospective Healthcare Utilisation for Community-Dwelling Older Adults with Complex Needs: A Matched Observational Study in Singapore
The global ageing population is associated with increased health service use. The PCMH care model integrates primary care and home-based care management to deliver comprehensive and personalised healthcare to community-dwelling older adults with bio-psycho-social needs. We examined if an integrated PCMH reduced healthcare utilisation burden of older persons in Singapore. We compared the healthcare utilisation between the intervention group and coarsened exact matched controls for a follow-up of 15 months. Baseline matching covariates included socio-demographics, health status, and past healthcare use. We accounted for COVID-19 social distancing effects on health-seeking behaviour. The intervention group consisted of 165 older adults with complex needs. We analysed national administrative healthcare utilisation data from 2017 to 2020. We applied multivariable zero-inflated regression modelling and presented findings stratified by high (CCI ≥ 5) and low disease burden (CCI < 5). Compared to controls, there were significant reductions in emergency department (β = −0.85; 95%CI = −1.55 to −0.14) and primary care visits (β = −1.70; 95%CI = −2.17 to −1.22) and a decrease in specialist outpatient visits (β = −0.29; 95%CI = −0.64 to 0.07) in the 3-month period immediately after one-year enrolment. The number of acute hospitalisations remained stable. Compared to controls, the intervention group with high and low comorbidity burden had significant decreases in primary care use, while only those with lower comorbidity burden had significant reductions in utilisation of other service types. An integrated PCMH appears beneficial in reducing healthcare utilisation for older persons with complex needs after 1 year in the programme. Future research can explore longer-term utilisation and scalability of the care model.
- Open Access
- 10 June 2023
- Published by Springer Nature in Eye
- Vol. 37 (18) , 3827-3833
The economic burden of inherited retinal disease in Singapore: a prevalence-based cost-of-illness study
Objective To assess the economic impact of inherited retinal disease (IRD) among Singaporeans. Methods IRD prevalence was calculated using population-based data. Focused surveys were conducted for sequentially enrolled IRD patients from a tertiary hospital. The IRD cohort was compared to the age- and gender-matched general population. Economic costs were expanded to the national IRD population to estimate productivity and healthcare costs. Results National IRD caseload was 5202 cases (95% CI, 1734–11273). IRD patients (n = 95) had similar employment rates to the general population (67.4% vs. 70.7%; p = 0.479). Annual income was lower among IRD patients than the general population (SGD 19,500 vs. 27,161; p < 0.0001). Employed IRD patients had lower median income than the general population (SGD 39,000 vs. 52,650; p < 0.0001). Per capita cost of IRD was SGD 9382, with a national burden of SGD 48.8 million per year. Male gender (beta of SGD 6543, p = 0.003) and earlier onset (beta of SGD 150/year, p = 0.009) predicted productivity loss. Treatment of the most economically impacted 10% of IRD patients with an effective IRD therapy required initial treatment cost of less than SGD 250,000 (USD 188,000) for cost savings to be achieved within 20 years. Conclusions Employment rates among Singaporean IRD patients were the same as the general population, but patient income was significantly lower. Economic losses were driven in part by male patients with early age of onset. Direct healthcare costs contributed relatively little to the financial burden.
- 10 June 2023
- Published by Springer Nature in Eye
- Vol. 37 (18) , 3827-3833
Open AccessThe economic burden of inherited retinal disease in Singapore: a prevalence-based cost-of-illness study
Objective To assess the economic impact of inherited retinal disease (IRD) among Singaporeans. Methods IRD prevalence was calculated using population-based data. Focused surveys were conducted for sequentially enrolled IRD patients from a tertiary hospital. The IRD cohort was compared to the age- and gender-matched general population. Economic costs were expanded to the national IRD population to estimate productivity and healthcare costs. Results National IRD caseload was 5202 cases (95% CI, 1734–11273). IRD patients (n = 95) had similar employment rates to the general population (67.4% vs. 70.7%; p = 0.479). Annual income was lower among IRD patients than the general population (SGD 19,500 vs. 27,161; p < 0.0001). Employed IRD patients had lower median income than the general population (SGD 39,000 vs. 52,650; p < 0.0001). Per capita cost of IRD was SGD 9382, with a national burden of SGD 48.8 million per year. Male gender (beta of SGD 6543, p = 0.003) and earlier onset (beta of SGD 150/year, p = 0.009) predicted productivity loss. Treatment of the most economically impacted 10% of IRD patients with an effective IRD therapy required initial treatment cost of less than SGD 250,000 (USD 188,000) for cost savings to be achieved within 20 years. Conclusions Employment rates among Singaporean IRD patients were the same as the general population, but patient income was significantly lower. Economic losses were driven in part by male patients with early age of onset. Direct healthcare costs contributed relatively little to the financial burden.